OMEGA DIAGNOSTICS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -16.2%

  £9,490,000 → £7,957,000

• Cash

  +66.6%

  £2,863,000 → £4,769,000

• Net assets

  +9.5%

  -£13,713,000 → -£12,411,000

• Employees

  -11%

  82 → 73

• Operating profit

  +283.5%

  -£644,000 → £1,182,000

• Profit before tax

  +302.5%

  -£643,000 → £1,302,000

• Wages

  -8.1%

  £3,227,000 → £2,965,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. OMEGA DIAGNOSTICS LIMITED 1987-12-16 → present
2. RANDOTTE (NO. 139) LIMITED 1987-10-15 → 1987-12-16

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“These financial statements have been prepared on a going concern basis, which contemplates the realisation of assets and the payment of liabilities in the ordinary course of business. The Company relies on its parent company, Cambridge Nutritional Sciences PLC for its funding needs and therefore a letter of support has been received from the Parent Company to support the going concern position.”

Significant events

• “In August 2024, Jag Grewal our CEO resigned from the Board having completed thirteen years of service.”
• “In August 2024, the Board appointed James Cooper as the new CEO, following his very successful role as Chief Operating Officer.”
• “In October we appointed a new Global Sales Director to build a global sales team and pipeline of opportunities.”
• “The recruitment of an experienced FTSE Chief Financial Officer, Ajay Patel who joined the board in July 2025. In addition, we also hired an Operations Director and a Marketing Communication Director to strengthen the leadership team.”
• “During the year the Company and DHSC have agreed settlement terms on a 'drop hands' basis with no admission of liability, with the effect that DHSC will not pursue its claim relating to reimbursement of pre-production payments and Omega will not pursue its claims in relation to additional losses arising from DHSC's failure to place orders for LFTs. The agreement reached is in full and final settlement of all claims held by either party arising from the Letter of Intent and Contract. Each party will bear its own legal costs.”
• “The new In Vitro Diagnostic Regulations (IVDR) that will be required for CE marking must be adhered to by the end of 2029 when the transition period ends.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.